The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: COX-2 selective inhibitors are associated with myocardial infarction (MI). We sought to determine whether population health monitoring would have revealed the effect of COX-2 inhibitors on population-level patterns of MI. METHODOLOGY/PRINCIPAL FINDINGS: We conducted a retrospective study of inpatients at two Boston hospitals, from January 1997 to March 2006. There was a population-level rise in the rate of MI that reached 52.0 MI-related hospitalizations per 100,000 (a two standard deviation exceedence) in January of 2000, eight months after the introduction of rofecoxib and one year after celecoxib. The exceedence vanished within one month of the withdrawal of rofecoxib. Trends in inpatient stay due to MI were tightly coupled to the rise and fall of prescriptions of COX-2 inhibitors, with an 18.5% increase in inpatient stays for MI when both rofecoxib and celecoxib were on the market (P<0.001). For every million prescriptions of rofecoxib and celecoxib, there was a 0.5% increase in MI (95%CI 0.1 to 0.9) explaining 50.3% of the deviance in yearly variation of MI-related hospitalizations. There was a negative association between mean age at MI and volume of prescriptions for celecoxib and rofecoxib (Spearman correlation, -0.67, P<0.05). CONCLUSIONS/SIGNIFICANCE: The strong relationship between prescribing and outcome time series supports a population-level impact of COX-2 inhibitors on MI incidence. Further, mean age at MI appears to have been lowered by use of these medications. Use of a population monitoring approach as an adjunct to pharmacovigilence methods might have helped confirm the suspected association, providing earlier support for the market withdrawal of rofecoxib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“High profile failures to detect safety problems during the preapproval period have brought new intense scrutiny on the drug approval process.[35,36,37,38,39] Revelation of an association between rofecoxib and MI [32,35,40,41] was a signal event highlighting catastrophic failures in monitoring the safety of therapeutic…”
BackgroundCardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 2×
“[9,10,11,12,13,14,15,17,27] Further, mean age at MI appears to”
BackgroundRisk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Physical Exertion as a Trigger of Acute Myocardial Infarction
Willich, S. N., Lewis, M., Lowel, H., Arntz, H.-R., Schubert, F., & Schroder, R. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312023292302 · Cited by 682 · cited 1×
“[1,2] Rates of MI have increased over the last century and are attributable to lifestyle risk factors, including smoking, obesity, exercise and diet.[3,4,5] While non-cardiovascular target drugs such as fenfluramine, dexfenfluramine, terfanadine and cisapride have been shown to be risk factors for cardiovascular events”
BackgroundThe lessons of Vioxx—drug safety and sales
Waxman, H. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058136 · Cited by 99
Cited by
Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis
Harpaz, R., DuMouchel, W., Shah, N. H., Madigan, D., Ryan, P., & Friedman, C. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.50 · Cited by 393
Theken, K. N., Lee, C. R., Gong, L., Caudle, K. E., Formea, C. M., Gaedigk, A., Klein, T. E., Agúndez, J. A. G., & Grosser, T. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1830 · Cited by 351
Using electronic health records to drive discovery in disease genomics
Kohane, I. S. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2999 · Cited by 325
Self-citationInterpreting noncoding genetic variation in complex traits and human disease
Ward, L. D., & Kellis, M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2422 · Cited by 6
Metadata
- Authors
- Brownstein, J. S., Sordo, M., Kohane, I. S., & Mandl, K. D.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-09-05
- Volume
- 2
- Issue
- 9
- Pages
- e840
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2119567793
- Cited by
- 69
- References
- 5
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction. https://app.cochat.ai/papers/10.1371/journal.pone.0000840
- The paper
- Brownstein, J. S., Sordo, M., Kohane, I. S., & Mandl, K. D. (2007). The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction. PLoS ONE. https://doi.org/10.1371/journal.pone.0000840
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.